Where does Elotuzumab-based combination therapy, specifically EPd, fit in your treatment paradigm for relapsed MM?
Does sequence matter?
Community PollStarted
When do you use elotuzumab combinations in patients with relapsed multiple myeloma?
16 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on · Updated on
The ELOQUENT-2 study evaluated Elotuzumab+Len/Dex vs Len/Dex alone showing improved PFS that was statistically significant and 4-year OS proportion of 50% vs 43% (HR 0.78, 95% CI 0.63-0.96). This required patients essentially be lenalidomide naive in 90% of the study population - something that is v...
Join for free or sign in to see the full answer